Stock of the Day: Could Endo International plc – Ordinary Shares Decline After Today’s Significant Increase?

Stock of the Day: Could Endo International plc   Ordinary Shares Decline After Today's Significant Increase?

The stock of Endo International plc – Ordinary Shares (NASDAQ:ENDP) is a huge mover today! About 2.46M shares traded hands. Endo International plc – Ordinary Shares (NASDAQ:ENDP) has declined 53.50% since March 2, 2016 and is downtrending. It has underperformed by 61.76% the S&P500.
The move comes after 5 months positive chart setup for the $4.54 billion company. It was reported on Oct, 5 by We have $30.85 PT which if reached, will make NASDAQ:ENDP worth $1.95B more.

Analysts await Endo International plc – Ordinary Shares (NASDAQ:ENDP) to report earnings on November, 3. They expect $0.84 EPS, down 17.65% or $0.18 from last year’s $1.02 per share. ENDP’s profit will be $176.80 million for 6.42 P/E if the $0.84 EPS becomes a reality. After $0.86 actual EPS reported by Endo International plc – Ordinary Shares for the previous quarter, Wall Street now forecasts -2.33% negative EPS growth.

Endo International plc – Ordinary Shares (NASDAQ:ENDP) Ratings Coverage

Out of 16 analysts covering Endo International plc (NASDAQ:ENDP), 9 rate it a “Buy”, 0 “Sell”, while 7 “Hold”. This means 56% are positive. Endo International plc has been the topic of 35 analyst reports since August 11, 2015 according to StockzIntelligence Inc. Mizuho downgraded the shares of ENDP in a report on Friday, May 6 to “Underperform” rating. The rating was upgraded by Northland Capital on Thursday, September 29 to “Outperform”. The rating was maintained by Stifel Nicolaus on Friday, May 6 with “Buy”. The firm has “Neutral” rating by Mizuho given on Monday, November 16. The stock has “Buy” rating given by Mizuho on Friday, October 9. The company was downgraded on Friday, May 6 by Leerink Swann. Barclays Capital maintained the stock with “Equal Weight” rating in Friday, May 6 report. The stock of Endo International plc – Ordinary Shares (NASDAQ:ENDP) has “Market Perform” rating given on Wednesday, December 9 by Northland Capital. The stock has “Neutral” rating given by Goldman Sachs on Monday, June 6. The firm has “Outperform” rating given on Thursday, April 21 by JMP Securities.

According to Zacks Investment Research, “Endo International plc is a global specialty healthcare company. It develops, manufactures, markets, and distributes quality branded pharmaceutical and generic products as well as medical devices. Endo offers branded prescription products, including Lidoderm, Opana ER, Percocet, Voltaren Gel, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel for pain, urology, endocrinology, and oncology. The company also provides non-branded generic products in the pain management, urology, central nervous system disorders, immunosuppression, oncology, women’s health, and hypertension markets. Endo International plc, formerly known as Endo Pharmaceuticals Holdings Inc., is headquartered in Dublin, Ireland.”

Insitutional Activity: The institutional sentiment increased to 0.95 in 2016 Q2. Its up 0.03, from 0.92 in 2016Q1. The ratio improved, as 76 funds sold all Endo International plc – Ordinary Shares shares owned while 90 reduced positions. 42 funds bought stakes while 115 increased positions. They now own 192.40 million shares or 1.49% more from 189.57 million shares in 2016Q1.
The New York-based D E Shaw And has invested 0% in Endo International plc – Ordinary Shares (NASDAQ:ENDP). Deerfield Mngmt owns 30,000 shares or 0.02% of their US portfolio. Empyrean Cap Prns Ltd Partnership has 900,000 shares for 0.63% of their US portfolio. Mitsubishi Ufj Bk Corp, a Japan-based fund reported 421,215 shares. Mycio Wealth Prns Ltd Liability holds 0.04% or 14,360 shares in its portfolio. Gotham Asset Mgmt Limited Liability Company, a New York-based fund reported 1.04 million shares. Gamble Jones Invest Counsel has invested 0.02% of its portfolio in Endo International plc – Ordinary Shares (NASDAQ:ENDP). Ls Invest Advsrs Limited Co has invested 0.01% of its portfolio in Endo International plc – Ordinary Shares (NASDAQ:ENDP). Diam Limited last reported 223,720 shares in the company. Advisors Asset Management owns 4,967 shares or 0% of their US portfolio. California Public Employees Retirement System last reported 432,600 shares in the company. Tctc Limited Liability Company accumulated 70,544 shares or 0.07% of the stock. Louisiana State Employees Retirement Systems has 0.01% invested in the company for 13,400 shares. Clearbridge Invests Ltd Llc has 0% invested in the company for 10,067 shares. Commonwealth Retail Bank Of last reported 1,467 shares in the company.

More news for Endo International plc – Ordinary Shares (NASDAQ:ENDP) were recently published by:, which released: “Endo International plc – Ordinary Shares (ENDP) Shares Soar” on August 09, 2016.‘s article titled: “Why, Inc. (CRM), Endo International plc – Ordinary Shares (ENDP …” and published on August 15, 2016 is yet another important article.

ENDP Company Profile

Endo International plc, incorporated on October 31, 2013, is a global specialty pharmaceutical firm focused on developing, manufacturing, marketing and distributing branded and generic pharmaceutical products, as well as over-the-counter medications through its operating companies- Endo Pharmaceuticals, Par Pharmaceutical, Paladin Labs and SOMAR. The Company’s divisions include U.S. Branded Pharmaceuticals, which offer portfolio of branded pharmaceuticals such as Lidoderm, OPANA ER, Voltaren Gel, Percocet, BELBUCA, Fortesta Gel, Testim, Aveed, Supprelin LA, and XIAFLEX; U.S. Generic Pharmaceuticals portfolio consists of tablets, capsules, powders, injectables, liquids, nasal sprays, ophthalmics and patches, and International Pharmaceuticals segment includes various specialty pharmaceutical products for the Canadian, Latin American, South African and world markets. It sells generic products primarily in the United States across multiple therapeutic categories.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Tags: ,

Leave a Comment